Influence of prostaglandins and PG-analogues on the mortality of PAF-acether in mice and the TXB2 release from human granulocytes.
The PAF-acether mortality in female mice varied with strains: AB mice were very resistant, NMRI mice showed dose-dependent effects. We used an i.v. injection of 75 micrograms/kg PAF-acether resulting in a 75% mortality in NMRI mice. Nileprost and PGE1 in one tenth of the doses of iloprost or PGI2 were able to reduce the PAF-acether mortality. Nalador, PGE2 and flunoprost were ineffective. 10 min after PAF application the TXB2 content in tail skin was increased significantly. The inhibitory effect on the TXB2 release induced by A 23187 from human granulocytes was stronger by nileprost than by iloprost. Nalador was ineffective, flunoprost enhanced the release. The lowered TXB2 formation is a possible explanation for the prevention of the PAF-acether induced death by PGs.
Becker
K
K
Department of Pharmacology and Toxicology, Martin Luther University, Halle-Wittenberg, GDR.
Förster
W
W
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D015237:Dinoprost / Q000378:metabolism; D006098:Granulocytes / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D008815:Mice, Inbred Strains; D010972:Platelet Activating Factor / Q000494:pharmacology*; D011453:Prostaglandins / Q000494:pharmacology*; D011465:Prostaglandins, Synthetic / Q000494:pharmacology*; D012867:Skin / Q000187:drug effects / Q000378:metabolism*; D013045:Species Specificity; D013929:Thromboxane B2 / Q000378:metabolism
D010972:Platelet Activating Factor; D011453:Prostaglandins; D011465:Prostaglandins, Synthetic; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D015237:Dinoprost